NCT02882789View on ClinicalTrials.gov

IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Healthy
Interventions
DRUG

LCB01-0371

Cohort1 \& 3: Placebo-controlled, Single ascending dose administration

DRUG

LCB01-0371 400mg

Cohort 2: Crossover designed administration

Trial Locations (1)

05505

Bae KS, Seoul

Sponsors
All Listed Sponsors
lead

LigaChem Biosciences, Inc.

INDUSTRY

NCT02882789 - IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter